Next-Day Discharge after TAVR: Equally Safe for All Prosthesis?

Yet scarce, there is evidence supporting next-day discharge (NDD) after TAVR is safe when patients receiving balloon expandable valves meet certain conditions. This had not yet been shown for self-expandable valves. This study looks into NDD after TAVR by femoral access with self-expandable valves. 

El alta en el mismo día luego de una angioplastia coronaria es cada vez más popular pero todavía no es regla

The authors retrospectively compared all consecutive patients undergoing elective minimalist TAVR between January 2017 and July 2018. They looked at next-day discharge success rate and the factors that prevent this from happening.

In addition, results were compared at 90 days and one year after next-day discharge with self-expandable ACURATE neo and balloon expandable SAPIEN 3.


Read also: The Most Read Articles in Interventional Cardiology in SOLACI.


During this period, 315 valves were implanted, 146 patients received the ACURATE neo and 103 received the SAPIEN 3.

60% of ACURATE neo patients (n=87) and 55% of the SAPIEN 3 patients (n=57) were discharged the next day after TAVR, which makes no significant difference.

Predictors preventing NDD after TAVR were chronic obstructive pulmonary disease (OR: 0.49) and baseline anemia (OR 0.98), but not valve type.


Read also: Functional Assessment of Lesions: Advances with MRI.


After excluding cases with more hospitalization days, there were no differences at 90 days in mortality (0% vs 0%) or new pacemaker implantation (1% vs 0%); p=0.40) between both devices. Something similar was observed with mortality at one year (8% vs 10%; p>0.8).

Conclusion

Safety of NDD using the self-expandable ACURATE neo was similar to NDD with SAPIEN 3, with comparable results at 90 days and one year.

Original Title: Safety of Next-Day Discharge After Transfemoral Transcatheter Aortic Valve Replacement With a Self-Expandable Versus Balloon-Expandable Valve Prosthesis.

Reference: Moriyama N et al. Circ Cardiovasc Interv. 2019 Jun;12(6):e007756.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...